NDAORALSUSPENSIONPriority Review
Approved
Feb 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
Priority Review
MEPRON (atovaquone) by GSK. Approved for antimalarial [epc]. First approved in 1995.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEPRON (atovaquone) is an oral antimalarial suspension approved in 1995 for treatment and prevention of malaria. It is a small-molecule antiprotozoal agent that works by inhibiting mitochondrial electron transport in Plasmodium parasites. The drug is primarily used in patients unable to tolerate first-line antimalarials or in cases of drug-resistant malaria.
$0.32MPart D
LOE ApproachingMinimal commercial activity with only 183 Part D claims in 2023 signals a niche, declining product with likely small brand team support.
Mechanism of Action
Pharmacologic Class:
Antimalarial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
Started Dec 2020
21 enrolled
Locally Advanced Non-Small Cell Lung Cancer
Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension
Started Apr 2012
30 enrolled
Malaria
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
Started Jul 2004
244 enrolled
Malaria, Falciparum
Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children
24 enrolled
Pneumonia, Pneumocystis CariniiHIV Infections
A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides
700 enrolled
Pneumonia, Pneumocystis CariniiHIV Infections
Worked on MEPRON at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.